Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — J.P. Morgan Global Healthcare Conference 2018
19 slides from Amneal Pharmaceuticals's conference presentation, Jan 9, 2018
Slide 1: J.P. Morgan Global Healthcare Conference
+ J.P. Morgan Global Healthcare Conference January 9, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- look
Slide 3: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitatio
Slide 4: A Strategic Combination for Long-Term Growth
A Strategic Combination for Long-Term Growth Creates 5th largest U.S. generics company Increases scale and diversification ~292 products filed and in development Enhances commercial product portfolio ~200 marketed product families 8 global R&D centers 11 global manufacturing facilities Combination A
Slide 5: Combination Fuels Long-Term Growth
Combination Fuels Long-Term Growth Annual double-digit revenue, adjusted EBITDA Estimated Adjusted EBITDA*** ($billions) and adjusted EPS growth over next 3 years Accretive to Impax’s adjusted EPS in the first 12 ~22% months after close* CAGR ~$1.1 $200 million in expected annual synergies wit
Slide 6: Poised for Success in Evolving Market Dynamics
Poised for Success in Evolving Market Dynamics Filed generic pipeline contains industry leading, high-value product opportunities* across multiple dosage forms Fully diversified, cost efficient manufacturing and development capability focused on delivering high-value generic product opportunitie
Slide 7: 2017 Achievements
2017 Achievements Amneal Impax 35 new products launched 9 new products launched 36 ANDAs approved; 9 tentatively approved 7 ANDAs approved; 2 tentatively approved 48 ANDAs filed 5 ANDAs filed Launched traimcinolone injection (first Positive phase IIb study for IPX203 generic) Annou
Slide 8: Combination Enhances Commercial Position
Combination Enhances Commercial Position #1 or #2 position in ~50% of commercial portfolio* Provides greater revenue diversification Top 5 generic product net revenue contribution ~26%** Opportunity to further capture long-term benefits of New Amneal development engine Examples NewCo has i
Slide 9: Broad R&D Capabilities Across Dosage Forms
Broad R&D Capabilities Across Dosage Forms Piscataway, NJ: Oral Solids, Liquids, Topicals, Transdermals Cashel, Ireland: Branchburg, NJ: Respiratory Liquids, Inhalation, Nasal Sprays Hayward, CA: Oral Solids Hyderabad, India: Injectables Brookhaven, NY: Ahmedabad, India: Oral Solids 3 Facilities: •
Slide 10: Diversified, High-Value New Amneal Pipeline
Diversified, High-Value New Amneal Pipeline ~292 total projects in the combined pipeline, of which ~50%+ are high value opportunities(1) FILINGS ~154 ANDAS DEVELOPMENT PIPELINE ~138 PROJECTS Ophthalmic 1% Transdermal 3% Nasal Spray 1% Other 4% Nasal Spray 2% Other 3% 4 21 Transdermal 4% 3 5 Topical
Slide 11: Specialty Provides Stable Cash Flow
Specialty Provides Stable Cash Flow Product Therapeutic Area Parkinson’s Disease Migraine Anthelmintic Anthelmintic 11
Slide 12: Diverse and Extensive Manufacturing Capabilities
Diverse and Extensive Manufacturing Capabilities Piscataway, NJ: Complex and High Value Products, Manufacturing Topicals, Transdermals, High Potency and Hormonal Products Distribution Branchburg, NJ: Cashel, Ireland: Oral Liquid Products, Nasal Sprays MDI, DPI Dahej, India: Active Pharmaceutical Ing
Slide 13: Significant Synergy Opportunity
Significant Synergy Opportunity $200 million in expected annual synergies within 3 years* Builds on Impax’s existing cost improvement plan Enhanced internal capabilities and less reliance on 3rd party manufacturing, reducing costs and improving margin Run-rate Synergies Achieved by: ($ in million
Slide 14: Integration Update
Integration Update Enhanced leadership of combined company Robert Stewart to serve as President and CEO Paul Bisaro to serve as Executive Chairman Chirag Patel and Chintu Patel will be Co-Chairmen of the Board Pre-close integration work well underway Regulatory review process progressing
Slide 15: Significant Benefit from US Tax Reform
Significant Benefit from US Tax Reform ~33% Non-GAAP ~20-24%* 2017 Tax Rate 2018 Additional Cash Flow Targeted for Debt Reduction and Investment in Growth Initiatives The benefits of tax reform are not included in the $200 million of expected annual cost synergies. *Range of estimated rate is the re
Slide 16: Path Forward
Path Forward INVEST IN • Generics: Continuing internal R&D investment focused on all seven dosage forms ORGANIC • Specialty: Continuing focus on Movement Disorders pipeline and opportunistically GROWTH in-license external opportunities MAINTAIN • Maintain high level of Quality and Compliance CUSTOME
Slide 17: Appendix
Appendix
Slide 18: Transaction Overview & Terms
Transaction Overview & Terms Transaction Summary Deal Terms All equity business combination New Amneal leadership Pro forma ownership: Amneal Holdings 75% / Impax Paul Bisaro will be Executive Chairman shareholders: 25%(1) Chirag and Chintu Patel will be Co-Chairmen of the Board New Amne
Slide 19: Combined PIV Disclosed Pending ANDA Pipeline
Combined PIV Disclosed Pending ANDA Pipeline Product Brand LTM IMS Sales Product Brand LTYM IMS Sales Pemetrexed injection Alimta® $1,028 Guaifenesin + Dextromethorphan HBr Mucinex® DM $76 Lubiprostone Capsule Amitiza® $489 Dronaderone Tablet Multaq® $448 Testosterone Gel 1.62% Androgel® $1,049 Mema
Amneal Pharmaceuticals — J.P. Morgan Global Healthcare Conference 2018 on 6ix